If you think you are paying too much for medications, it’s worth investigating.
Here are ways you might be able to get the medications you need at a lower cost.
The approvals of tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) in 2019 were a victory for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). These new agents slow the development of heart failure and reduce the 30-month mortality rate from 43% to 30%. But at $225,000 a year, the drugs may be unaffordable for many. Medicare Part D […]
To continue reading this article or issue you must be a paid subscriber. Sign in